

REMARKS

Applicants thank the Examiner for consideration of the subject patent application. In the office action mailed May 28, 2009, Claims 1-45 were pending, and made subject to restriction requirement and further to an election of species requirement under 35 U.S.C. § 121. Particularly, the Examiner indicated the existence of five patentably distinct inventions in the claims as follows: 1) Group I constituting Claims 1-26 and 32-34, drawn to a conjugate comprising a full length or fragment of an amyloid protein; 2) Group II constituting Claims 27-31 drawn to a method for treatment of an amyloid-related disease in a mammal, comprising administering an antigenic amount of a conjugate comprising an amyloid protein; 3) Group III constituting Claims 35-38 drawn to a method of producing a polyclonal or monoclonal antibody; 4) Group IV constituting an antibody having specificity towards an amyloid protein; and 5) Group V constituting Claims 44-45, drawn to a method for the treatment of an amyloid-related disease in a mammal, comprising administering an antibody that has specificity for an amyloid protein. The Examiner further indicated the existence of seventeen patentably distinct species of amyloid protein as follows:

- a) serum amyloid A protein (ApoSSA)
- b) immunoglobulin light chain
- c) immunoglobulin heavy chain
- d) ApoA1
- e) Transthyretin
- f) Lysozyme
- g) Fibrinogen alpha chain

- h) Gelsolin
- i) Cystatin C
- j) Amyloid beta protein precursor (beta-APP)
- k) Betas microglobulin
- l) Prion precursor protein (PrP)
- m) Atrial natriuretic factor
- n) Keratin
- o) Islet amyloid polypeptide
- p) Synuclein
- q) Amyloid beta peptide

Finally, the Examiner indicated that Claim 1 was generic with respect to Group I.

A review of Claims 1-26 and 32-34 in Group I reveals that Claims 1-5, 7-26 and 32-34 read on an amyloid beta peptide as indicated by Species (q). Therefore, pursuant to the present election of Group I, Species (q), Claims 1-5, 7-26, and 32-34 remain pending for consideration in the present application, and Claims 6, 27-31, and 35-45 are withdrawn.

CONCLUSION

If any impediment remains to examination after consideration of the above-recited remarks, which could be removed during a telephone interview, the Examiner is invited to telephone the undersigned attorney, at (801) 566-6633 so that such issues may be resolved as expeditiously as possible.

The Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 20-0100.

DATED this 30th day of November, 2009.

Respectfully submitted,

THORPE, NORTH & WESTERN, LLP

/David W. Osborne/

David W. Osborne
Reg. No. 44,989
8180 South 700 East, Suite 350
Sandy, UT 84070
Telephone: (801) 566-6633
Facsimile: (801) 566-0750